press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

23 september 2021

ind application for pivotal clinical study of pd-l1/ctla-4 bispecific antibody kn046 for pd-(l)1 refractory nsclc was approved by cde this is the third pivotal clinical study of kn046 after the first one in treatment naïve squamous nsclc and the second one in thymic carcinoma.
17 september 2021

preliminary efficacy and safety results of kn026 in combination with kn046 in patients with her2-positive gastrointestinal tumors presented at esmo 2021 for her2-positive patients, orr was 51.9% and the median dor was 11.2 months. the orr was 71.4% for treatment naïve patients.
17 september 2021

poster highlighting clinical data of kn046 in combination with lenvatinib as first-line treatment for hepatocellular carcinoma presented at esmo 2021 kn046 in combination with lenvatinib in 1st line hcc achieved 57% and 76% orr and 95% and 95% dcr by recisct 1.1 and imrecist, respectively.
17 september 2021

alphamab presented poster highlighting clinical data of kn046 combined with chemotherapy as first line treatment in patients with advanced nsclc at esmo 2021 orr was 50%. dcr was 91.7%. mpfs was 8.7 months. median overall survival (mos) was not reached, and os rate was 100% at 6 months.
30 august 2021

alphamab oncology reports 2021 interim results and business highlights alphamab oncology always focuses on the clinical value and patient needs.
24 august 2021

alphamab oncology and cspc achieved an licensing cooperation on anti-her2 bispecific antibody kn026 in mainland china the totaldeal size reaches 1 billion rmb, and the company will receive a double-digit royalty based on sales revenue.
17 august 2021

major progress in her2 bispecific antibody! alphamab oncology kn026 liquid formulation was approved for clinical use the approval of this liquid formulation for clinical research will provide more convenience to patients and medical staff for administration,and lay a good foundation for the development of subcutaneo...
16 august 2021

alphamab oncology announces first patient dosed in phase2 clinical study of kn026 for the neoadjuvant treatment of her2 positive breast cancer we look forward to bringing new adjuvant treatments with better efficacy and safety to patients with early or locally advanced breast cancer, improving the chances of cure through a higher rate of rad...
26 july 2021

new data from alphamab oncology’s kn046 and kn026 to be presented at the esmo congress 2021 abstract release time: 00:05 cest on september 13, 2021
30 june 2021

subcutaneously injected pd-l1 antibody envafolimab (kn035) obtained its second orphan drug designation from the u.s. fda this is the second orphan drug designation for envafolimab after its first odd in advanced biliary tract cancer and fourth odd that alphamab oncology has obtained from the u.s. fda.